Match!
Nikolay M. Borisov
I.M. Sechenov First Moscow State Medical University
42Publications
14H-index
859Citations
Publications 41
Newest
#2Maxim SorokinH-Index: 9
Last.Anton BuzdinH-Index: 9
view all 5 authors...
Source
#1Anton BuzdinH-Index: 26
#2Andrew GarazhaH-Index: 10
Last.Nurshat Gaifullin (MSU: Moscow State University)H-Index: 8
view all 11 authors...
e13032Background: Intracellular molecular pathways (IMPs) control all major events in the living cell. They are considered hotspots in contemporary oncology because knowledge of IMPs activation is ...
Source
#1Elena PoddubskayaH-Index: 6
#2Anton BuzdinH-Index: 26
Last.Nikolay M. Borisov (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 14
view all 17 authors...
e13143Background: Anticancer Targeted Drugs (ATDs) specifically target one or a few types of tumor-related molecules in a cell. More than two hundred of ATDs were approved worldwide. They have diff...
1 CitationsSource
#1Marianna A. Zolotovskaia (RSMU: Russian National Research Medical University)H-Index: 2
#2Maxim Sorokin (RAS: Russian Academy of Sciences)H-Index: 9
Last.Anton Buzdin (RAS: Russian Academy of Sciences)H-Index: 26
view all 8 authors...
Despite the significant achievements in chemotherapy, cancer remains one of the leading causes of death. Target therapy revolutionized this field, but efficiencies of target drugs show dramatic variation among individual patients. Personalization of target therapies remains, therefore, a challenge in oncology. Here, we proposed molecular pathway-based algorithm for scoring of target drugs using high throughput mutation data to personalize their clinical efficacies. This algorithm was validated o...
9 CitationsSource
#1Marianna A. Zolotovskaia (RSMU: Russian National Research Medical University)H-Index: 2
#2Maxim Sorokin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
Last.Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
view all 5 authors...
DNA mutations play a crucial role in cancer development and progression. Mutation profiles vary dramatically in different cancer types and between individual tumors. Mutations of several individual genes are known as reliable cancer biomarkers, although the number of such genes is tiny and does not enable differential diagnostics for most of the cancers. We report here a technique enabling dramatically increased efficiency of cancer biomarkers development using DNA mutations data. It includes a ...
7 CitationsSource
#1Nikolay M. Borisov (Kurchatov Institute)H-Index: 14
#2Victor TkachevH-Index: 5
Last.Anton Buzdin (Kurchatov Institute)H-Index: 9
view all 4 authors...
Development of individual predictors of clinical drug efficiency becomes the mainstream in modern oncology. According to this approach, for a given patient with known type of cancer and a chosen drug, we should be able to estimate the treatment effect caused by the drug. Almost all works in this field apply machine learning techniques, which perform deep statistical analysis of a set of clinical cases supported by gene expression data for every patient. This important approach, unfortunately, su...
3 CitationsSource
#1Anton BuzdinH-Index: 9
#2Nikolay M. BorisovH-Index: 14
Source
#1Alexander AliperH-Index: 20
#2Michael KorzinkinH-Index: 2
Last.Nikolay M. Borisov (Kurchatov Institute)H-Index: 14
view all 9 authors...
13 CitationsSource
#1Anton BuzdinH-Index: 26
#2Vladimir Prassolov (EIMB: Engelhardt Institute of Molecular Biology)H-Index: 17
Last.Nikolay M. Borisov (Kurchatov Institute)H-Index: 14
view all 4 authors...
13 CitationsSource
#1Anton Buzdin (Kurchatov Institute)H-Index: 9
Last.Alla A. KushchH-Index: 1
view all 13 authors...
ABSTRACTResponses to human cytomegalovirus (HCMV) infection are largely individual and cell type specific. We investigated molecular profiles in 2 primary cell cultures of human fibroblasts, which are highly or marginally sensitive to HCMV infection, respectively. We screened expression of genes and microRNAs (miRs) at the early (3 hours) stage of infection. To assess molecular pathway activation profiles, we applied bioinformatic algorithms OncoFinder and MiRImpact. In both cell types, pathway ...
5 CitationsSource
12345